Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
Nurix and Sanofi sign $50 million pact on targeted protein degradation
by Michael McCoy
January 10, 2020
| A version of this story appeared in
Volume 98, Issue 2
Sanofi will pay Nurix Therapeutics $55 million up front and up to $2.5 billion in future milestones to collaborate on targeted protein degradation therapies. Nurix will use DNA-encoded libraries and E3 ligases to create small molecules designed to induce degradation—rather than mere inhibition—of three specified protein drug targets. Nurix signed a similar deal with Gilead Sciences in June that was focused on cancer and other diseases. Biotech firms like Arvinas and Kymera Therapeutics are also developing protein degraders
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter